Close

 

In 2018, Domain Therapeutics and Boehringer Ingelheim entered into a multi-target collaboration and licensing agreement to address orphan GPCR for neuropsychiatric disorders and potential other indications (see press release).

Program description

Multi-target collaboration for CNS

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

Initiated in 2018, the multi-target drug discovery collaboration focuses on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area. The collaboration combines our expertise in the discovery of orphan GPCR targeting drugs in CNS, oncology and immuno-oncology, with Boehringer Ingelheim’s expertise in the discovery and clinical development of therapeutics on multiple indications.

The achievement of two discovery milestones was announced in September 2019.

Other Programs

First-in-class anti-GPCR antibody for immuno-oncology

Discover

First-in-class CXCR4 agonist to control auto-immune diseases

Discover